Circulating soluble Fas in patients with breast cancer

Shyr Ming Sheen-Chen, Han Shiang Chen, Hock Liew Eng, Wei Jen Chen

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

It has been suggested that circulating soluble Fas (sFas) contributes to tumor progression. However, little is known about the role of sFas in breast cancer. This study was designed with the aim of elucidating the possible relation between sFas and breast cancer. A series of 57 consecutive patients with invasive breast cancer undergoing surgery were prospectively included in the study and evaluated. Venous blood samples were collected before surgery. Sera were obtained by centrifugation and stored at -70°C until assayed. The control group consisted of 12 patients with benign breast tumors (6 with fibrocystic disease, 6 with fibroadenoma). Serum concentrations of sFas were measured by the quantitative sandwich enzyme immunoassay technique. The data on primary tumor staging, age, estrogen receptor status, lymph node status, tumor grading, and TNM staging were reviewed and recorded. The mean value of circulating sFas in patients with invasive breast cancer was 794.2 ± 183.0 pg/ml and that of the control group 582.1 ± 62.8 pg/ml; the difference was significant (p < 0.001). Furthermore, there were significantly higher serum levels of sFas in the older patients (age ≥ 50) (p = 0.020) and in those with a more advanced TNM stage (p = 0.021). In the multivariate analysis, TNM stage (p = 0.005) appeared to be an independent factor for significantly higher circulating sFas in patients with invasive breast cancer. Thus circulating sFas levels may reflect the severity of invasive breast cancer. Hence the possible prognostic value of sFas for breast cancer deserves further elucidation and evaluation with long-term patient follow-up.

Original languageEnglish
Pages (from-to)10-13
Number of pages4
JournalWorld Journal of Surgery
Volume27
Issue number1
DOIs
Publication statusPublished - Jan 1 2003
Externally publishedYes

Fingerprint

Breast Neoplasms
Neoplasm Staging
Serum
Fibroadenoma
Control Groups
Neoplasm Grading
Immunoenzyme Techniques
Centrifugation
Estrogen Receptors
Multivariate Analysis
Lymph Nodes
Neoplasms

ASJC Scopus subject areas

  • Surgery

Cite this

Circulating soluble Fas in patients with breast cancer. / Sheen-Chen, Shyr Ming; Chen, Han Shiang; Eng, Hock Liew; Chen, Wei Jen.

In: World Journal of Surgery, Vol. 27, No. 1, 01.01.2003, p. 10-13.

Research output: Contribution to journalArticle

Sheen-Chen, Shyr Ming ; Chen, Han Shiang ; Eng, Hock Liew ; Chen, Wei Jen. / Circulating soluble Fas in patients with breast cancer. In: World Journal of Surgery. 2003 ; Vol. 27, No. 1. pp. 10-13.
@article{69fce61d8daa4e629717bed1dd0519d9,
title = "Circulating soluble Fas in patients with breast cancer",
abstract = "It has been suggested that circulating soluble Fas (sFas) contributes to tumor progression. However, little is known about the role of sFas in breast cancer. This study was designed with the aim of elucidating the possible relation between sFas and breast cancer. A series of 57 consecutive patients with invasive breast cancer undergoing surgery were prospectively included in the study and evaluated. Venous blood samples were collected before surgery. Sera were obtained by centrifugation and stored at -70°C until assayed. The control group consisted of 12 patients with benign breast tumors (6 with fibrocystic disease, 6 with fibroadenoma). Serum concentrations of sFas were measured by the quantitative sandwich enzyme immunoassay technique. The data on primary tumor staging, age, estrogen receptor status, lymph node status, tumor grading, and TNM staging were reviewed and recorded. The mean value of circulating sFas in patients with invasive breast cancer was 794.2 ± 183.0 pg/ml and that of the control group 582.1 ± 62.8 pg/ml; the difference was significant (p < 0.001). Furthermore, there were significantly higher serum levels of sFas in the older patients (age ≥ 50) (p = 0.020) and in those with a more advanced TNM stage (p = 0.021). In the multivariate analysis, TNM stage (p = 0.005) appeared to be an independent factor for significantly higher circulating sFas in patients with invasive breast cancer. Thus circulating sFas levels may reflect the severity of invasive breast cancer. Hence the possible prognostic value of sFas for breast cancer deserves further elucidation and evaluation with long-term patient follow-up.",
author = "Sheen-Chen, {Shyr Ming} and Chen, {Han Shiang} and Eng, {Hock Liew} and Chen, {Wei Jen}",
year = "2003",
month = "1",
day = "1",
doi = "10.1007/s00268-002-6378-5",
language = "English",
volume = "27",
pages = "10--13",
journal = "World Journal of Surgery",
issn = "0364-2313",
publisher = "Springer New York LLC",
number = "1",

}

TY - JOUR

T1 - Circulating soluble Fas in patients with breast cancer

AU - Sheen-Chen, Shyr Ming

AU - Chen, Han Shiang

AU - Eng, Hock Liew

AU - Chen, Wei Jen

PY - 2003/1/1

Y1 - 2003/1/1

N2 - It has been suggested that circulating soluble Fas (sFas) contributes to tumor progression. However, little is known about the role of sFas in breast cancer. This study was designed with the aim of elucidating the possible relation between sFas and breast cancer. A series of 57 consecutive patients with invasive breast cancer undergoing surgery were prospectively included in the study and evaluated. Venous blood samples were collected before surgery. Sera were obtained by centrifugation and stored at -70°C until assayed. The control group consisted of 12 patients with benign breast tumors (6 with fibrocystic disease, 6 with fibroadenoma). Serum concentrations of sFas were measured by the quantitative sandwich enzyme immunoassay technique. The data on primary tumor staging, age, estrogen receptor status, lymph node status, tumor grading, and TNM staging were reviewed and recorded. The mean value of circulating sFas in patients with invasive breast cancer was 794.2 ± 183.0 pg/ml and that of the control group 582.1 ± 62.8 pg/ml; the difference was significant (p < 0.001). Furthermore, there were significantly higher serum levels of sFas in the older patients (age ≥ 50) (p = 0.020) and in those with a more advanced TNM stage (p = 0.021). In the multivariate analysis, TNM stage (p = 0.005) appeared to be an independent factor for significantly higher circulating sFas in patients with invasive breast cancer. Thus circulating sFas levels may reflect the severity of invasive breast cancer. Hence the possible prognostic value of sFas for breast cancer deserves further elucidation and evaluation with long-term patient follow-up.

AB - It has been suggested that circulating soluble Fas (sFas) contributes to tumor progression. However, little is known about the role of sFas in breast cancer. This study was designed with the aim of elucidating the possible relation between sFas and breast cancer. A series of 57 consecutive patients with invasive breast cancer undergoing surgery were prospectively included in the study and evaluated. Venous blood samples were collected before surgery. Sera were obtained by centrifugation and stored at -70°C until assayed. The control group consisted of 12 patients with benign breast tumors (6 with fibrocystic disease, 6 with fibroadenoma). Serum concentrations of sFas were measured by the quantitative sandwich enzyme immunoassay technique. The data on primary tumor staging, age, estrogen receptor status, lymph node status, tumor grading, and TNM staging were reviewed and recorded. The mean value of circulating sFas in patients with invasive breast cancer was 794.2 ± 183.0 pg/ml and that of the control group 582.1 ± 62.8 pg/ml; the difference was significant (p < 0.001). Furthermore, there were significantly higher serum levels of sFas in the older patients (age ≥ 50) (p = 0.020) and in those with a more advanced TNM stage (p = 0.021). In the multivariate analysis, TNM stage (p = 0.005) appeared to be an independent factor for significantly higher circulating sFas in patients with invasive breast cancer. Thus circulating sFas levels may reflect the severity of invasive breast cancer. Hence the possible prognostic value of sFas for breast cancer deserves further elucidation and evaluation with long-term patient follow-up.

UR - http://www.scopus.com/inward/record.url?scp=0037637678&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037637678&partnerID=8YFLogxK

U2 - 10.1007/s00268-002-6378-5

DO - 10.1007/s00268-002-6378-5

M3 - Article

C2 - 12557031

AN - SCOPUS:0037637678

VL - 27

SP - 10

EP - 13

JO - World Journal of Surgery

JF - World Journal of Surgery

SN - 0364-2313

IS - 1

ER -